Ajanta Pharma is primarily engaged in development, manufacturing and marketing of speciality pharmaceutical quality finished dosages.(Source : 202003-01 Annual Report Page No:70).
Financial Results:
Ajanta Pharma Ltd reported Revenues for Q3FY24 of ₹1,105.00 Crores up from ₹972.00 Crore year on year, a rise of 13.68%.
Total Expenses for Q3FY24 of ₹827.00 Crores down from ₹838.00 Crores year on year, a fall of 1.31%.
Consolidated Net Profit of ₹210.00 Crores up 55.56% from ₹135.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹16.68, up 58.86% from ₹10.50 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.